相似文献
1
Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues.
J Med Chem. 2007 Feb 22;50(4):713-25. doi: 10.1021/jm061071x. Epub 2007 Jan 31.
2
Synthesis of novel macrocyclic docetaxel analogues. Influence of their macrocyclic ring size on tubulin activity.
J Med Chem. 2003 Aug 14;46(17):3623-30. doi: 10.1021/jm030770w.
3
Rotational-echo double-resonance NMR distance measurements for the tubulin-bound Paclitaxel conformation.
J Am Chem Soc. 2007 Jan 17;129(2):361-70. doi: 10.1021/ja0656604.
4
Design and synthesis of (+)-discodermolide-paclitaxel hybrids leading to enhanced biological activity.
J Med Chem. 2011 Sep 22;54(18):6319-27. doi: 10.1021/jm200692n. Epub 2011 Aug 26.
5
The bioactive Taxol conformation on beta-tubulin: experimental evidence from highly active constrained analogs.
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10006-11. doi: 10.1073/pnas.0403459101. Epub 2004 Jun 28.
6
A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cancer Lett. 2013 Dec 1;341(2):214-23. doi: 10.1016/j.canlet.2013.08.010. Epub 2013 Aug 11.
7
Bridging converts a noncytotoxic nor-paclitaxel derivative to a cytotoxic analogue by constraining it to the T-Taxol conformation.
Org Lett. 2006 Aug 31;8(18):3983-6. doi: 10.1021/ol061438s.
8
Syntheses and bioactivities of macrocyclic paclitaxel bis-lactones.
Bioorg Med Chem. 2004 Dec 1;12(23):6147-61. doi: 10.1016/j.bmc.2004.09.002.
9
Design and synthesis of de novo cytotoxic alkaloids by mimicking the bioactive conformation of paclitaxel.
Bioorg Med Chem. 2010 Oct 1;18(19):7101-12. doi: 10.1016/j.bmc.2010.07.069. Epub 2010 Aug 6.
10
The cytotoxic natural compound erianin binds to colchicine site of β-tubulin and overcomes taxane resistance.
Bioorg Chem. 2024 Sep;150:107569. doi: 10.1016/j.bioorg.2024.107569. Epub 2024 Jun 17.
引用本文的文献
1
Artemisiae Annuae Herba: from anti-malarial legacy to emerging anti-cancer potential.
Theranostics. 2025 Jun 20;15(15):7346-7377. doi: 10.7150/thno.115414. eCollection 2025.
2
A Small Sugar Molecule with Huge Potential in Targeted Cancer Therapy.
Pharmaceutics. 2023 Mar 11;15(3):913. doi: 10.3390/pharmaceutics15030913.
3
A kNGR Peptide-Tethered Lipid-Polymer Hybrid Nanocarrier-Based Synergistic Approach for Effective Tumor Therapy: Development, Characterization, Ex-Vivo, and In-Vivo Assessment.
Pharmaceutics. 2022 Jul 3;14(7):1401. doi: 10.3390/pharmaceutics14071401.
4
Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein.
Front Oncol. 2021 Oct 21;11:752127. doi: 10.3389/fonc.2021.752127. eCollection 2021.
5
Natural products in drug discovery: advances and opportunities.
Nat Rev Drug Discov. 2021 Mar;20(3):200-216. doi: 10.1038/s41573-020-00114-z. Epub 2021 Jan 28.
6
Structure Activity Relationship of Key Heterocyclic Anti-Angiogenic Leads of Promising Potential in the Fight against Cancer.
Molecules. 2021 Jan 21;26(3):553. doi: 10.3390/molecules26030553.
7
Synergistic Enhancement of Paclitaxel-induced Inhibition of Cell Growth by Metformin in Melanoma Cells.
Dev Reprod. 2019 Jun;23(2):119-128. doi: 10.12717/DR.2019.23.2.119. Epub 2019 Jun 30.
8
Residual Complexity Does Impact Organic Chemistry and Drug Discovery: The Case of Rufomyazine and Rufomycin.
J Org Chem. 2018 Jun 15;83(12):6664-6672. doi: 10.1021/acs.joc.8b00988. Epub 2018 May 24.
9
Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery.
J Nat Prod. 2018 Mar 23;81(3):703-721. doi: 10.1021/acs.jnatprod.7b01012. Epub 2018 Feb 22.
10
Prodrug Strategies for Paclitaxel.
Int J Mol Sci. 2016 May 23;17(5):796. doi: 10.3390/ijms17050796.
本文引用的文献
1
Rotational-echo double-resonance NMR distance measurements for the tubulin-bound Paclitaxel conformation.
J Am Chem Soc. 2007 Jan 17;129(2):361-70. doi: 10.1021/ja0656604.
2
Bridging converts a noncytotoxic nor-paclitaxel derivative to a cytotoxic analogue by constraining it to the T-Taxol conformation.
Org Lett. 2006 Aug 31;8(18):3983-6. doi: 10.1021/ol061438s.
3
The T-Taxol conformation.
J Med Chem. 2006 Apr 20;49(8):2478-88. doi: 10.1021/jm051119r.
4
Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
Eur J Cancer. 2006 May;42(7):934-47. doi: 10.1016/j.ejca.2005.12.018. Epub 2006 Mar 15.
5
Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.
Cancer Res. 2006 Jan 1;66(1):212-20. doi: 10.1158/0008-5472.CAN-05-1997.
6
Conformations of laulimalide in DMSO-d6.
J Am Chem Soc. 2005 Sep 21;127(37):12838-46. doi: 10.1021/ja042890e.
7
Use of the tubulin bound paclitaxel conformation for structure-based rational drug design.
Chem Biol. 2005 Mar;12(3):339-48. doi: 10.1016/j.chembiol.2005.01.004.
8
The taxol pharmacophore and the T-taxol bridging principle.
Cell Cycle. 2005 Feb;4(2):279-89. Epub 2005 Mar 1.
9
Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
Cancer Res. 2004 Dec 1;64(23):8708-14. doi: 10.1158/0008-5472.CAN-04-2538.
10
Synthesis of C2-C3'N-linked macrocyclic taxoids. Novel docetaxel analogues with high tubulin activity.
J Med Chem. 2004 Nov 18;47(24):5937-44. doi: 10.1021/jm0497996.
Zotero 插件